#National Cancer Institute

The study findings “have the potential to open up new avenues for therapeutic intervention in this subset of GIST tumors.”

A movement toward a greater focus on patient-reported outcomes is afoot.

A conversation with Kathryn Schmitz, PhD, MPH

Although the improvement in survival with immunotherapy was modest, it is noteworthy because SCLC has been such a recalcitrant disease.

Imagine, taking a simple blood draw to find out if you have cancer, and if so, the cancer’s location and molecular type.

The three studies tested Zejula, Lynparza and veliparib in women with newly diagnosed advanced ovarian cancer.

In a clinical trial, the research team is hoping to learn more about how myeloma cells resist CAR T-cell therapy.

“The more information we have from well-designed studies, the better we are able to counsel our patients,” said Larissa Korde, MD.

Oncolytic viruses kill cancer cells, but studies also suggest that they can boost the immune system’s ability to recognize and kill a tumor.

SPORE grants have become the cornerstone of NCI’s efforts to advance collaborative, interdisciplinary translational cancer research.

Scientists emphasize using data and analyses from completed and ongoing trials to gain a better understanding of patient outcomes.

Forty-five percent of 182 phase 3 clinical trials between 1980 and 2017 influenced guideline care or new drug approvals.

The study tested the effectiveness of CEASE, a program that aims to reduce children’s exposure to secondhand smoke by helping parents quit.

Funding will help enroll more minority and underserved patients in cancer clinical trials across Louisiana and Mississippi.

A new study suggests that, for people with pancreatic cancer, the makeup of the bacteria in their tumors could predict how long they live.

The researchers found that very few women reported discussing costs with their medical team, despite their desire to do so.